Company / Return on Equity (ROE)
enGene Holdings Inc. Return on Equity (ROE) History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-69.9%
FY2025
5-year range
-137.8% / -20.2%
FY2023-FY2025
Trend
-245.7%
vs FY2024
Sector context
#158 of 190
Health Care
What the data says
enGene Holdings Inc. reports negative total equity of -69.9% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-69.9% in FY2025.
Improved from -137.8% to -69.9% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 190This company -69.9% Sector average -29.0%
▼
-141.6% below sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 245.7% year-over-year.
- Currently 41.0pp below the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -69.9% | -245.7% |
| FY2024 | -20.2% | +85.3% |
| FY2023 | -137.8% | - |
| FY2022 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026